Did Aurobindo Destroy Its Credibility With FDA Along With A Microbial Plate?
This article was originally published in The Pink Sheet Daily
Executive Summary
A warning letter, an import alert and two recalls spell trouble for the Indian manufacturer.
You may also be interested in...
Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles
India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment
GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant
Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.